NAAA
ADMA icon

New Age Alpha Advisors’s ADMA Biologics ADMA Stock Holding History

New Age Alpha Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$93.9K Sell
11,219
-501
-4% -$4.57K ﹤0.01% 852
2026
Q1 		$106K Sell
11,720
-264
-2% -$4.17K ﹤0.01% 688
2025
Q4 		$219K Sell
11,984
-531
-4% -$8.95K 0.01% 596
2025
Q3 		$183K Sell
12,515
-550
-4% -$9.43K 0.01% 653
2025
Q2 		$238K Buy
13,065
+969
+8% +$19.8K 0.01% 597
2025
Q1 		$240K Sell
12,096
-777
-6% -$13.4K 0.01% 616
2024
Q4 		$221K Buy
+12,873
New +$242K 0.01% 641

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

New Age Alpha Advisors's ADMA Position: Q2 2026 in Review

New Age Alpha Advisors reduced its ADMA Biologics (ADMA) stake by 4.3% in Q2 2026, selling an estimated $4.57K and leaving 11,219 shares worth $93.9K. The position accounts for ﹤0.01% of the portfolio, ranked #852.

New Age Alpha Advisors first reported a position in ADMA in Q4 2024 and has held it in 7 quarters since. The position peaked at $240K in Q1 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • New Age Alpha Advisors held 11,219 shares of ADMA Biologics worth $93.9K as of Q2 2026.
  • New Age Alpha Advisors sold 501 ADMA Biologics shares in Q2 2026, an estimated $4.57K.
  • ADMA Biologics made up ﹤0.01% of New Age Alpha Advisors's portfolio in Q2 2026, its #852 holding.
  • New Age Alpha Advisors first reported a position in ADMA Biologics in Q4 2024 and has held it in 7 quarters since.
  • New Age Alpha Advisors's ADMA Biologics position peaked at $240K in Q1 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on New Age Alpha Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.